Latest Syndax News & Updates

See the latest news and media coverage for Syndax. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Syndax

Commercial-stage oncology company developing targeted cancer therapies

syndax.com
Headquarters
New York, United States
Company type
Public company
Number of employees
50–350

Latest news about Syndax

Company announcements

  • Syndax

    Syndax reports Q1 2026 financial results

    Total revenue reaches $64.9 million, up 224% YoY. Revuforj nets $48.9 million, Niktimvo collaboration $15.9 million. Upcoming data in 2Q26 and 4Q26.

  • Syndax

    Syndax schedules Q1 2026 earnings call

    The conference call and webcast occur on April 30 at 4:30 p.m. ET. A replay follows.

  • Syndax

    Syndax reports Q4 and full-year 2025 financial results

    Total revenue reaches $68.7M in Q4 and $172.4M for the year. Revuforj nets $44.2M in Q4, Niktimvo $56.0M. Phase 2 IPF trial enrollment completed; topline data due Q4 2026.

  • Syndax

    Syndax schedules conference call

    The call on February 26 at 4:30 p.m. ET discusses Q4 and full year 2025 financial results and business update. A replay follows.

Unlock all announcements with a

Media coverage

  • Medindia

    New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]

    Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA...

  • MSN

    Syndax, Kymera and Axos post growth while outlining 2026 milestones

    Syndax Pharmaceuticals, Kymera Therapeutics, and Axos Financial reported solid first-quarter results, highlighting product sales, partnerships, and strategic acquisitions. Each company reaffirmed key 2026 milestones, from...

  • Yahoo Finance

    Syndax: Q1 Earnings Snapshot

    Syndax Pharmaceuticals Inc. SNDX) on Thursday reported a loss of $42.7 million in its first quarter. The New York-based company said it had a loss...

  • Pharmaceutical Technology

    Merck KGaA, Pfizer, and Syndax Collaborate on Ovarian Cancer Treatment | Pharmaceutical Technology

    Merck KGaA, Pfizer, and Syndax enter into exclusive agreement to evaluate the use of avelumab and entinostat for ovarian cancer patients.

Unlock all articles with a

Never miss news about Syndax

Track Syndax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Syndax competitors & trending companies

Browse news for competitors to Syndax and other trending companies.